BeiGene, a global science-driven biotechnology company, launched an innovation center on Monday in Guangzhou, capital of Guangdong province, to enable scientists and entrepreneurs to accelerate development of highly differentiated, cutting-edge medical innovations.

The center is an innovator-centric incubator built to explore new paths to meet patients' needs, according to John V. Oyler, co-founder, chairman and chief executive officer of BeiGene.

"We are supporting entrepreneurs with similar purpose and vision of delivering innovation that will benefit more patients worldwide," said Oyler, adding the center will contribute to BeiGene's innovation pipeline.

The center, with an area of 39,948 square meters in the Guangdong-Hong Kong-Macao Greater Bay Area, features a comprehensive research infrastructure and professional management team.

According to Jonathan Liu, chief executive officer of Bio-Island Initiative and chairman of BeiGene Biologics Co Ltd, the center will be able to develop more than 30 new startups in the future.

"The center is focused on cultivating entrepreneurship for new biotech companies with a passion for transformational medicines, diagnostics and medical devices that can help address unmet needs, and advancing breakthrough innovations from early discovery to being accessed by patients all over the world," he said.

Scientists and entrepreneurs at the center will have potential access to support from BeiGene on full industry value chain integration, according to Liu.